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ORIGINAL ARTICLE
Background/Aims: The use of statins in patients with acute coronary syndrome (ACS) has increased, and
reduced levels of low-density lipoprotein cholesterol (LDL-C) lead to lower coronary event rates. We studied the
effect of lipid levels during statin treatment on prognosis in patients with ACS and percutaneous coronary
intervention (PCI).
Methods: Between January 2005 and May 2007, 325 ACS patients who underwent PCI and received statins
were evaluated. We measured serum lipid levels at baseline and 4 weeks. The relationships between on-
treatment levels of triglyceride (TG) and LDL-C and one-year major adverse cardiac events (MACE) were
assessed.
Results: At 4 weeks, the mean LDL-C level was 72.5±23.8 mg/dL and the mean TG was 123.2±62.8 mg/dL.
MACE occurred in 41 cases (12.6%). Baseline serum lipid levels were similar between the patients with and those
without MACE. However, the patients with MACE showed significantly higher TG level at 4 weeks (149.6±81.4 vs.
119.3±58.9 mg/dL, p=0.026) than those without. High on-treatment TG level (≥150 mg/dL) were associated with
increased adverse events compared to lower TG level in a univariate analysis (hazard ratio [HR], 3.3; p<0.001). In
a multivariate analysis, high 4-week TG level after statin treatment was an independent predictor for MACE (HR,
4.01; 95% confidence interval, 1.85 to 9.06; p=0.001), however, baseline TG and LDL-C levels were not.
Conclusions: High on-treatment TG level (≥150 mg/dL) was associated with a higher risk of MACE. This finding
supports the concept that achieving low TG levels may be an important therapeutic parameter in statin-treated
patients following ACS and PCI. (Korean J Intern Med 2009;24:330-336)
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INTRODUCTION
One of the targets most emphasized in risk reduction
for cardiovascular diseases is lowdensity lipoprotein
cholesterol (LDL-C). Recent large-scale lipid-lowering
trials have suggested that hydroxylmethyglutaryl-CoA
reductase inhibitors (statins) provide benefits in the
primary and secondary prevention of coronary artery
disease [1-4]. 
The benefits of statin treatment are mediated through
reducing LDL-C levels. A metaanalysis showed that
lowering LDL-C below 57 mg/dL can theoretically reduce
the rate of new coronary heart disease (CHD) event to
zero, and that lowering it below 67 mg/dL stopped the
progression of atherosclerosis [5]. Additionally, the
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syndrome (ACS) showed that high-dose statin therapy,
with a median LDL-C level of 62 mg/dL, was better than
the standard therapy [6]. Thus, the ‘lower is better’
hypothesis is currently accepted, and the National
Cholesterol Education Program-Adult Treatment Panel-
III (NCEP-ATP-III) guidelines also recommend that
target LDL-C be lower than 70 mg/dL in very high-risk
patients, including ACS patients [7].
Many clinical trials of statins have demonstrated signifi-
cant reductions in CHD events, compared with placebo
[8]. In general, however, a significant risk of coronary
events remains, so additional treatment methods are
necessary to further reduce the risk. 
Analyses of patients who received statins but still had
CHD events may indicate which factors are important for
additional risk reduction. Lipid-lowering trials have
shown that the lowest lipid levels after statin treatment
were achieved in the first month, and then the lowered
lipid level remained stable during the study period [6].
As a result, examination of lipid levels at one month and
analysis of its relationship with the CHD events may
provide information about whether LDL-C should be
further reduced or whether other targets should be
addressed.
We examined the on-treatment lipid levels at 4 weeks in
patients with ACS who received percutaneous coronary




Between January 2005 and May 2007, 350 consecutive
ACS patients who underwent PCI and received statins
before discharge were evaluated. Exclusion criteria
included ST-segment-elevation myocardial infarction
(MI), including true posterior MI, failed PCI, in-hospital
Table 1. Baseline characteristics of subjects according to absence or presence of major adverse cardiac events
MACE (-) MACE (+) p value
(n=284) (n=41)
Age, yr 62.8±10.5 61.0±10.0 0.585
Male 175 (61.6) 26 (63.4) 0.865
NSTEMI 69 (24.3) 13 (31.7) 0.337
Hypertension 149 (52.5) 22 (53.7) 1.000
Diabetes 94 (33.1) 12 (29.3) 0.723
Current smoker 109 (38.4) 18 (43.9) 0.499
Ejection fraction 60.3±10.7 61.0±10.4 0.704
Total cholesterol, mg/dL 198.0±46.0 201.2±46.6 0.679
Triglyceride, mg/dL 177.9±130.0 185.6±166.8 0.734
HDL-cholesterol, mg/dL 44.8±11.2 46.8±11.5 0.237
LDL-cholesterol, mg/dL 124.3±37.3 124.6±44.9 0.964
Troponin T, ng/mL 0.22±0.69 0.32±0.82 0.421
hsCRP, mg/L 4.2±8.3 4.6±9.7 0.799
Medication
ACEI/ARB 248 (87.3) 36 (87.8) 0.931
Beta blocker 163 (57.4) 22 (53.7) 0.652
Calcium antagonist 108 (38.0) 14 (34.1) 0.631
Multi-vessel disease 150 (52.8) 23 (56.1) 0.740
ACC/AHA type B2/C lesion 208 (73.2) 33 (80.5) 0.445
Drug-eluting stent 279 (98.6) 41 (100) 1.000
Procedural complication 34 (12.0) 3 (7.3) 0.597
Values are number (%) or mean±SD.
MACE, major adverse cardiac events; NSTEMI, non-ST-segment elevation myocardial infarction; HDL, high density lipoprotein; LDL, low density
lipoprotein; hsCRP, high sensitivity C-reactive protein; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker;
ACC/AHA, American College of Cardiology/American Heart Association lesion classification.332 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
Table 2. Lipid profiles after 4 weeks statin treatment
MACE (-) MACE (+) p value
(n=284) (n=41)
Total cholesterol, mg/dL 138.0±31.3 145.4±30.2 0.156
Triglyceride, mg/dL 119.3±58.9 149.6±81.4 0.026
HDL-cholesterol, mg/dL 46.7±11.7 45.7±9.7 0.543
LDL-cholesterol, mg/dL 71.8±23.3 77.6±26.7 0.150
Non HDL cholesterol, mg/dL 91.3±27.8 99.7±30.3 0.074
TG/HDL ratio 2.8±1.7 3.9±3.8 0.067
Percentage change of triglyceride -14.5±53.2 8.4±70.2 0.051
Percentage change of LDL-cholesterol -36.9±37.5 -33.3±26.7 0.557
Percentage change of HDL-cholesterol 6.1±3.7 0.7±3.9 0.150
hsCRP, mg/L 1.4±1.5 1.5±1.6 0.836
Values are mean±SD.
MACE, major adverse cardiac events; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglyceride; hsCRP, high sensitivity C-
reactive protein.
Figure 1. One-year event-free rate according to on-treatment 4-week lipid levels.
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MI, or repeated revascularization, allergy to statins,
administration of fibrates or fish oil, known inflammatory,
neoplastic, or infectious disease, and PCI within the
previous 12 months.
PCI was performed according to current clinical practice
at the physician’s discretion. Angiographic success of
PCI was defined as TIMI III flow, with residual stenosis
below 20%. All patients involved in the study had under-
gone successful procedures. After the procedure, the
patients received 75 mg of clopidogrel for 12 months and
aspirin indefinitely. Statins were dosed as soon as possible
after hospitalization, regardless of baseline lipid level, and
prior to discharge, at the latest. Angiotensin-converting
enzyme inhibitors and beta blockers were also prescribed
at the physician’s discretion.
Toal cholesterol, triglyceride (TG), and high-density
Table 4. Multivariate analysis for prediction of 1 year major adverse cardiac events
Odd ratio 95% Confidence interval p  value
4-wk TG ≥150 mg/dL 4.01 1.85-9.06 0.001
4-wk LDL-C ≥70 mg/dL 1.85 0.75-4.56 0.181
4-wk non-HDL-C ≥100 mg/dL 1.08 0.43-2.68 0.878
4-wk hsCRP ≥2 mg/L  1.53 0.67-3.52 0.312
Age 0.76 0.35-1.65 0.488
Ejection fraction 1.00 0.97-1.04 0.725
Hypertension 0.75 0.35-1.60 0.456
Diabetes mellitus 0.58 0.24-1.41 0.231
Body mass index 0.89 0.78-1.01 0.060
Serum creatinine 2.23 0.75-6.68 0.312
Serum glucose 1.00 0.99-1.01 0.310
TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein.
Table 3. Clinical characteristics according to the kinds of statin
Rosuvastatin Atorvastatin Ezetimibe/ Pitavastatin Simvastatin
Simvastatin
Number 221 (68.0) 42 (12.9) 37 (11.4) 17 (5.2) 8 (2.5)
Dose, mg 10±1 17±4 10/12±5 2±0 15±5
Baseline lipid profile, mg/dL
Total cholesterol 201±47 183±46 202±48 207±33 169±23*
Triglyceride 177±136 180±154 198±127 155±108 176±71
HDL-cholesterol 45±11 48±11 44±11 45±10 38±14
LDL-cholesterol 129±39 117±38 112±38 116±25 110±29
4-week lipid level, mg/dL
Total cholesterol 137±30 139±29 139±40 157±28 139±19
Triglyceride 119±59 141±87 120±50 137±72 129±46
HDL-cholesterol 47±11 49±12 44±12 46±12 43±14
LDL-cholesterol 72±25 77±18 70±24 77±22 77±21
MACE, n (%)
Death 3 (1.4) 2 (4.8) 0 (0.0) 0 (0.0) 0 (0.0)
Non fatal MI 4 (1.8) 0 (0.0) 0 (0.0) 1 (5.9) 0 (0.0)
Revascularization 20 (9.0) 6 (14.3) 2 (5.4) 2 (11.8) 1 (12.5)
Total 27 (12.2) 8 (19.0) 2 (5.4) 3 (17.6) 1 (12.5)
Values are number (%) or mean±SD.
HDL, high density lipoprotein; LDL, low density lipoprotein; MACE, major adverse cardiac events; MI, myocardial infarction.
*p<0.05 vs. rosuvastatin and pitavastatin group.334 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
lipoprotein cholesterol (HDL-C) were measured by an
automated chemial analyzer (Roche diagnostics, Mannheim,
Baden-Wurttemberg, Germany) after a 12 hour overnaight
fat. LDL-C was measured directly. Lipid and lipoprotein
levels were obtained at baseline, 4 weeks, 6 months, and
12 months.
The endpoint was defined as the occurrence of a major
adverse cardiac event (MACE), including cardiac death,
non-fatal MI, and any coronary repeated revascularization
(surgery or PCI). Only the first such event was counted as
the end point. Twelve months follow-up data were obtained
in a total of 325 patients; in 19 cases, statins were stopped,
and six cases of MACE occurred before 4 weeks, as deter-
mined by inspection of medical records or direct contact
with the patients. 
All patients gave informed consent according to a
protocol approved by the institutional review board of
the hospital.
Statistical analysis
All measurements are presented as mean±standard
deviation. Inter-group analysis was conducted using the
independent t-test, χ
2 test, or Fisher’s exact test, using
the SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). The
ANOVA test and Games-Howell test were performed to
compare statin groups. The Kaplan-Meier method was
used for cumulative MACE free survival analysis. Hazard
ratios (HR) and 95% confidence intervals (CI) were
calculated using selected cut-off points as references. Cut-
off points were derived from the NCEP-ATP-III guidelines
[7]: that is, LDL-C <70 mg/dL and triglycerides <150
mg/dL. Additionally, other selected cut-off points for
non-HDL-C <100 mg/dL and C-reactive protein (CRP)
<2 mg/L were evaluated [7,9,10]. The effect of covariates
on survival time was tested by Cox proportional-hazards
regression analysis. Statistical significance was set at
p<0.05.
RESULTS
A total of 325 patients were identified by the study
criteria. Of these, 68.0% received rosuvastatin, 12.9%
atorvastatin, 11.4% ezetimibe/simvastatin, 5.2%
pitavastatin, and 2.5% simvastatin. During 12 months of
follow-up, MACE occurred in 41 patients (12.6%) including
five cases of cardiac death, five cases of non-fatal MI, and
31 cases of repeated revascularization.
Baseline clinical characteristics and procedural variables
according to the occurrence of MACE are shown in Table
1. No significant difference was found in the most relevant
clinical characteristics between the two groups. We used
drug-eluting stents in most cases (98.5%), and over 33%
of the patients received multi-vessel stenting. All angio-
graphic and procedural characteristics were similar
between the groups.
At 4 weeks, the mean LDL-C level was 72.5±23.8
mg/dL and the mean TG was 123.2±62.8 mg/dL. Of the
patients, 49.8% had LDL-C ≥70 mg/dL, and 24.3% had
TG ≥150 mg/dL. The patients with MACE had significantly
higher on-treatment TG level than did those without
(149.6±81.4 vs. 119.3 ±58.9 mg/dL, p=0.026, Table 2).
Low on-treatment LDL-C (<70 mg/dL) was not associated
with MACE compared to higher LDLC in a univariate
analysis. Rather, fewer MACE were observed in patients
with low on-treatment TG level (HR, 3.3; 95% CI, 1.8 to
6.0; p<0.001) and low on-treatment non HDL-C (HR, 2.1;
95% CI, 1.1 to 3.8; p=0.019) compared to those with higher
levels of TG and non-HDL-C (Fig. 1).
Lipid levels and clinical outcomes according to the
statin used are shown in Table 3. Most patients were
treated with standard doses of statins. No significant
difference in 4-week lipid levels and MACE were found
according to the type of statin regimen. Multivariate
analysis revealed that on-treatment TG level was the only
significant independent predictor of MACE (Odd Ratio,
4.09; 95% CI, 1.85 to 9.06; p=0.001; Table 4). Baseline
lipid levels were not associated with MACE in patients
treated with statins.
DISCUSSION
This study demonstrates that on-treatment TG ≥150
mg/dL was associated with a higher risk of MACE. This
supports the concept that TG levels are an important
target in patients who undergo statin treatment.
LDL-C is a well-established risk factor for CHD.
Observational studies have consistently shown a positive
relationship between CHD risk and LDL-C levels [8,11,12].
Trials in both primary prevention and secondary prevention
settings have shown that the risk of suffering a CHD event
during the course of the study was closely related to
ontreatment LDL [1-4,13]. Thus, the NCEP-ATP-III
guidelines also recommend that the target LDL-C be
lower than 70 mg/dL in very high-risk patients, includingYun KH, et al. On-treatment triglyceride level after PCI    335
ACS patients [7]. However, lipid-lowering therapy using
statins led to a relative risk reduction of only 25-30% in
most large randomized controlled trials [8]. Thus, factors
other than LDL-C may be important: the recently published
INTERHEART study emphasized dyslipidemia as an
important risk factor, and the NCEP-ATP-III considers
non-HDL-C as a secondary target [14].
Our findings emphasize that lowering TG is necessary,
beyond lowering LDL-C, in patients treated with statins. A
meta-analysis of observational studies of TG and CHD
events showed that an 89 mg/dL increase in TG level had
an independent risk prediction rate of 14% in men and
37% in women [15]. A recent meta-analysis of 29 published
reports showed about a 70% increase in primary CHD
events in men and women in the highest, compared with
the lowest, tertile of the TG distribution, even after adjusting
for age, gender, smoking, and lipid measurements [16].
The importance of on-treatment TG has also been demon-
strated in other studies. A large prospective Chinese study
found TG to be predictive of CHD mortality, even in a
setting of low total cholesterol [17]. In analyses of the
PROVE IT-TIMI 22 trial, low on-treatment TG (<150
mg/dL) was associated with reduced CHD risk compared
with higher TG after adjustment for LDL-C [18].
Some reports have shown that TG is an important factor
in atherosclerosis. In a hypertriglyceridemic state, the
accumulation of remnants results in a proinflammatory
and oxidative milieu that may enhance the expression of
adhesion molecules, foam cell formation, and smooth
muscle cell toxicity [19]. High TG levels cause increases in
small dense LDL, the substance that most readily causes
atheroclerosis, and also reduce HDL, thereby accelerating
atherosclerosis [20]. The correlation between plasma TG
and atherogenic remnants is coupled with the excess risk
of CHD with combined elevations of LDL-C and TG [17].
Thus, a strategy combining lowering of both LDL-C and
TG, rather than intensive LDL-C-lowering therapy alone,
would be more effective for the treatment of patients with
ACS.
LDL-C, HDL-C, and CRP were less important in the
present study, which may have been due to the limitations
of this small observational study or might be characteristic
of patients already treated with statins. All patients
received powerful statin treatment, so their average lipid
profile was well controlled and below target levels; this
may have resulted in the relatively lower importance of
other risk factors. However, this study should not be
understood to detract from the importance of those risk
factors. Rather, it is desirable to understand the results of
this research as emphasizing the powerful control of TG in
addition to the traditional risk factors.
Limitations of this study include: 1) weak statistical
power due to the small patient group and the low event
rate; 2) the original purpose of this research was not to
prove the hypothesis that combined low on-treatment
LDL and TG is better than low ontreatment LDL-C; 3)
because the statin regimens used in the patients were not
same, treatment agent may be another confounding
variable; and 4) the failure in presenting the target levels
of on treatment TG. Our findings obviously need to be
complemented by future large-scale randomized trials.
In conclusion, on-treatment TG ≥150 mg/dL was
associated with a higher risk of MACE. This finding
supports the concept that achieving low TG may be an
important therapeutic parameter in statin-treated patients
following ACS and PCI.
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